In general, ICB has shown relevant benefits across many cancer entities, however in several oncogene-driven tumors responses have been disappointing, e.g. in ALK- or EGFR-driven lung cancer54,55, where ICB may even be related with severely increased adverse event rates in certain scenarios56. The gene discussed is ALK; the disease is cancer.